4DMT Announces Promising Financial Results and Key Clinical Developments
March 1, 2025 - 00:01
4DMT has reported encouraging interim data from its ongoing clinical trials, showcasing significant advancements in its treatment for wet age-related macular degeneration (AMD) and diabetic macular edema (DME). The results from the PRISM Phase 1/2 trial for 4D-150 indicate robust and durable clinical activity across a diverse patient population, with a favorable tolerability profile observed over a 52-week period and beyond.
In addition to the AMD findings, the company also revealed positive interim results from the SPECTRA clinical trial, specifically from Part 1, which focuses on DME. These 32-week data results are pivotal as they demonstrate the potential effectiveness of 4D-150 in treating this condition.
Moreover, 4DMT has achieved alignment with the FDA regarding its development strategy, indicating that a single Phase 3 trial could be sufficient for a Biologics License Application (BLA) submission for 4D-150 in DME, especially when combined with data from the 4FRONT study. This strategic direction marks a significant milestone for the company as it seeks to advance its therapeutic offerings in the ophthalmology space.
MORE NEWS
February 2, 2026 - 10:07
Hana Financial Group Seeks ‘Balanced Growth’ With Non-Bank TurnaroundHana Financial Group has announced a strategic pivot for the coming year, prioritizing a turnaround at its non-banking affiliates to achieve what it terms `balanced growth.` This move signals a...
February 1, 2026 - 19:29
I’m a 66-year-old retired homeowner in Fort Worth, sitting on $143,000 in cash. What should I do with my money?A retired homeowner in Fort Worth, aged 66, is thoughtfully considering the next steps for a substantial $143,000 cash reserve. This scenario highlights a common and crucial crossroads for many...
February 1, 2026 - 05:33
Bitcoin Retreats Below $80,000 as Market Sees Influx of New InvestorsThe price of Bitcoin has fallen below the psychologically significant $80,000 threshold, introducing a note of caution into the recent bullish market sentiment. This dip represents a period of...
January 31, 2026 - 06:28
Is Pathward Financial (CASH) Still Attractively Priced After Strong Recent Share Price GainsInvestors are closely examining Pathward Financial`s stock valuation after a period of significant share price appreciation. The financial services provider has delivered robust returns across...